We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
SARS-CoV-2 seroprevalence and respiratory disease disability claims in Mexico City Metropolitan Area.
- Authors
Barros-Sierra, David; Zepeda-Tello, Rodrigo; Tamayo-Ortiz, Marcela; Osiris Gutiérrez-Díaz, Hector; Aurora Pérez-Chávez, Valeria; Antonio Rosa-Parra, José; Enrique Nieto-Barajas, Luis; Méndez-Aranda, Mauricio; Alonso Herrera-Montalvo, Luis; Hernández-Ávila, Mauricio
- Abstract
Objective. To characterize the impact of SARS-CoV-2 infection in workers from an essential large-scale company in the Greater Mexico City Metropolitan Area using point prevalence of acute infection, point prevalence of past infection through serum antibodies and respiratory disease short-term disability claims (RD-STDC). Materials and methods. Four randomized surveys, three during 2020 before and one after (December 2021) vaccines’ availability. Outcomes: point prevalence of acute infection through saliva PCR (polymerase chain reaction) testing, point prevalence of past infection through serum antibodies against Covid-19, RD-STDC and prevalence of symptoms during the previous six months. Results. Prevalence of SARS-CoV-2 cases was 1.29-4.88%, on average, a quarter of participants pre-vaccination were seropositive; over half of participants with a RD-STDC had antibodies. The odds of having antibodies were 6-7 times more among workers with an RD-STDC. Conclusions. High antibody levels against Covid-19 in this study population reflects that coverage is high among workers in this industry. STDCs are a useful tool to track workplace epidemics.
- Subjects
MEXICO City (Mexico); DISABILITY insurance claims; METROPOLITAN areas; RESPIRATORY diseases; SARS-CoV-2; SEROPREVALENCE
- Publication
Salud Pública de México, 2023, Vol 65, Issue 4, p334
- ISSN
0036-3634
- Publication type
Article
- DOI
10.21149/14545